NEW YORK (GenomeWeb) – CardioDx today announced that Aetna has established a clinical policy for the Corus CAD gene expression test for coronary artery disease.

As a result, members of Aetna and Coventry Health Care will have access to the test. According to Aetna's website, it serves about 44 million lives. Coventry, which Aetna acquired in 2013, has about 5 million members. CardioDx said that Aetna considers the test medically necessary for evaluating non-diabetic adults with chest pain or anginal equivalent symptoms but who have no prior history of obstructive CAD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.